XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Numerator          
Net loss $ (38,466) $ (34,823) $ (73,799) $ (71,732)  
Less: Net loss attributable to noncontrolling interest $ (25,960) $ (25,705) $ (51,801) $ (52,949)  
Antidilutive securities          
Earnout Rights     17,500,000 17,500,000  
Stock options granted under the 2022 Equity Incentive Plan 21,916,121 15,718,932 21,916,121 15,718,932  
Restricted Stock Rights [Member]          
Antidilutive securities          
Unvested Restricted Stock Rights     2,188,728 5,952,288  
Common Class A [Member]          
Numerator          
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic $ (12,506) $ (9,118) $ (21,998) $ (18,783)  
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted $ (12,506) $ (9,118) $ (21,998) $ (18,783)  
Denominator          
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic 75,908,017 64,562,209 68,429,869 64,551,281  
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted 75,908,017 64,562,209 68,429,869 64,551,281  
Net loss per share attributable to Class A ordinary shares, Basic $ (0.16) $ (0.14) $ (0.32) $ (0.29)  
Net loss per share attributable to Class A ordinary shares, Diluted $ (0.16) $ (0.14) $ (0.32) $ (0.29)  
Antidilutive securities          
ProKidney Corp. ordinary shares 125,856,877   125,856,877   59,880,347
Common Class B [Member]          
Antidilutive securities          
ProKidney Corp. ordinary shares 163,817,953 173,663,427 163,817,953 173,663,427 168,297,916